SCHEMBL840404

SCHEMBL840404

CC(C)N1CCCN(C(C)C)C1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.33
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840554 0.93 CHRNA7 (0.33) CHRNA7
SCHEMBL104677 0.86
SCHEMBL840178 0.86 CHRNA7 (0.42) CHRNA7SIGMAR1
SCHEMBL840162 0.86 CHRNA7 (0.36) CHRNA7
SCHEMBL1093168 0.86
SCHEMBL13290565 0.86 CHRNA7 (0.42) CHRNA7SIGMAR1
SCHEMBL9322170 0.83 ALDH1A1 (0.30)
SCHEMBL24435951 0.83 CHRNA7 (0.40) CHRNA7SIGMAR1
SCHEMBL18157902 0.83 CHRNA7 (0.35) CHRNA7
SCHEMBL840810 0.83 CHRNA7 (0.40) CHRNA7SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220129-A1 BENZOYPARAZINE PYRAZINES ANE THEIR USES FOGHORN THERAPEUTICS INC. (US) 2023-11-16 WO disclosed
US-11712485-B2 Triazine based radiopharmaceuticals and radioimaging agents MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) 2023-08-01 US disclosed
US-11713344-B2 Acylated oxyntomodulin peptide analog DONG-A ST CO., LTD. (KR) 2023-08-01 US disclosed
US-11713344-B2 Acylated oxyntomodulin peptide analog DONG-A ST CO., LTD. (KR) 2023-08-01 US disclosed
WO-2023116835-A1 MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON 苏州开拓药业股份有限公司 2023-06-29 WO disclosed
US-20220119473-A1 ACYLATED OXYNTOMODULIN PEPTIDE ANALOG DONG-A ST CO., LTD. (KR) 2022-04-21 US disclosed
EP-2444438-B1 POLYMERIZABLE COMPOSITION, RESIN MOLDED BODY, AND LAMINATE ZEON CORP (JP) 2020-03-18 EP disclosed
WO-2019238629-A1 PYRIDINYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed
WO-2019238616-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-12-19 WO disclosed
EP-2977388-B1 COPOLYMER RUBBER CONTAINING NITRILE GROUP, CROSSLINKABLE RUBBER COMPOSITION, AND RUBBER CROSSLINKED PRODUCT ZEON CORP (JP) 2019-09-04 EP disclosed
US-20090030014-A1 Indole Derivative Having Pgd2 Receptor Antagonist Activity SHIONOGI & CO., LTD. (JP) 2009-01-29 US disclosed
EP-2017308-A1 OXYGEN-ABSORBING RESIN COMPOSITION Kuraray Co., Ltd. (JP) 2009-01-21 EP disclosed
US-7465773-B2 Polymerizable composition and formed article using the same ZEON CORPORATION (JP) 2008-12-16 US disclosed
US-7381782-B2 Polymerizable composition and molded articles produced by using the same ZEON CORPORATION (JP) 2008-06-03 US disclosed
US-20060258828-A1 Polymerizable composition and molded articles produced by using the same ZEON CORPORATION (JP) 2006-11-16 US disclosed
US-20060211809-A1 Polymerizable composition and formed article using the same ZEON CORPORATION (JP) 2006-09-21 US disclosed
EP-1655321-A1 POLYMERIZABLE COMPOSITIONS AND MOLDED ARTICLES PRODUCED BY USING THE SAME Zeon Corporation (JP) 2006-05-10 EP disclosed
EP-1652885-A1 POLYMERIZABLE COMPOSITION AND FORMED ARTICLE USING THE SAME Zeon Corporation (JP) 2006-05-03 EP disclosed
EP-1640153-A1 MULTILAYER BODY AND METHOD FOR PRODUCING SAME Zeon Corporation (JP) 2006-03-29 EP disclosed
US-20050014916-A1 Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst ZEON CORPORATION (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11712485-B2 Triazine based radiopharmaceuticals and radioimaging agents PSMA2, PSMA5, PSMA1 CHRNA7 4477/4885SIGMAR1 2691/4885
US-11713344-B2 Acylated oxyntomodulin peptide analog GLP1R, GIPR, GPR119 CHRNA7 1279/4885SIGMAR1 787/4885
US-20220119473-A1 ACYLATED OXYNTOMODULIN PEPTIDE ANALOG GLP1R, GIPR, GPR119 CHRNA7 1279/4885SIGMAR1 787/4885
US-20050014916-A1 Ruthenium complexes, process for preparation thereof, and processes for producing open-ring polymer of cycloolefins and hydrogenation products thereof by using the complex as catalyst POR, CAD, HRH1 CHRNA7 2099/4885SIGMAR1 3082/4885
US-20090030014-A1 Indole Derivative Having Pgd2 Receptor Antagonist Activity HRH2, PTGDR, CNR2 CHRNA7 640/4885SIGMAR1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.